BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  Submission of the dossier 
The  applicant  Eli  Lilly  Nederland  B.V.  submitted  on  29  July  2003  an  application  for 
Marketing  Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products 
(EMEA) for Alimta, through the centralised procedure. After agreement by the CHMP on 14 
August  2003,  this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council 
Regulation No (EEC) 2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: 
Co-Rapporteur:  
Dr Eric Abadie   
Prof Tilman Ott 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 19 October 2000. The Scientific 
Advice pertained to the clinical aspects of the dossier.  
Licensing status: 
A new application was filed in the following countries: USA. 
1.2  Steps taken for the assessment of the product 
The procedure started on 18 August 2003. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 28 
October  2003.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all 
CHMP members on 30 October 2003 
During the  meeting  on  16-17 December 2003,  the  CHMP agreed  on  the  consolidated 
List of Questions to be sent to the applicant. The final consolidated List of Questions 
was sent to the applicant on 18 December 2003. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 
12 March 2004. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to 
the List of Questions to all CHMP members on  27 April 2004. 
During the CHMP meeting on 1-3 June 2004, the CHMP agreed on a list of outstanding 
issues to be addressed in writing by the applicant. 
The applicant submitted the responses to the CHMP list of outstanding issues on 8 June 
2004. 
The  Rapporteurs  circulated  the  updated  Joint  Assessement  Report  on  the  applicant’s 
responses to the list of outstanding Issues on 11 and 14 June 2004. 
During  the  meeting  on  22-23  June  2004,  the  CHMP,  in  the  light  of  the  overall  data 
submitted and the scientific discussion within the Committee, issued a positive opinion 
for  granting  a  Marketing  Authorisation  to  Alimta  on  23  June  2004.  The  applicant 
provided  the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-
authorisation on 22 June 2004.  
The CHMP opinions were forwarded, in all official languages of the European Union, 
to  the  European  Commission,  which  adopted  the  corresponding  Decisions  on  20 
September 2004. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
. 
1/1 
EMEA 2004 
 
 
 
 
 
 
